Several recent studies suggest that the demonstration of ras p 21 may serve as el useful marker of tumor proliferation and in the prognosis of the malignant patient.In this study, immunohistochemical investigation was performed to elucidate possible correlations between ras p 21 products and disease prognosis, and/or other factors.
Demonstration of ras p 21 products in 48 oral squamous cell carcinomas and 15 benign lesions was investigated using a monoclonal anti-ras p 21 antibody in the avidin-biotinperoxidase complex method.
Immunohistochemical demonstration of ras p 21 products was observed in 54.2%(26/48) of squamous cell carcinomas and in 20%(3/15) of benign lesions.Demonstration of ras p 21 products bore no correlation with clinical stage, incidence of lymph node metastasis or recurrence rate. They were, however demonstrated in 67.6%(25/37) of differentiated squamous cell carcinomas, but in only 9.1%(1/11) of poorly differentiated cancers. These results suggest that demonstration of ras p 21 products cannot be considered a reliable marker of malignancy and that ras p 21 is associated with cellular differentiation rather than cell proliferation.